Ferrer Receives FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP)
BARCELONA, Spain--(BUSINESS WIRE)--Ferrer, a B Corp-certified international pharmaceutical company, has announced that FNP-223, a novel therapy in-licensed from Asceneuron and aimed at slowing the development of progressive supranuclear palsy (PSP), has received Fast Track designation from the US Food & Drug Administration (FDA). FNP-223, a new molecular entity in active development for PSP, is in an ongoing Phase 2 study to evaluate its safety, efficacy, and pharmacokinetics in adult patients with possible or probable PSP-Richardson syndrome (PSP-RS), the most common clinical variant of this neurodegenerative disease 1.
We are thrilled to receive Fast Track designation from the FDA for FNP-223 in the treatment of PSP. Consistent with our purpose of using business to fight for social justice, we are committed to advancing this promising therapy to patients.
Share
'We are thrilled to receive Fast Track designation from the FDA for FNP-223 in the treatment of PSP. Consistent with our purpose of using business to fight for social justice, we are committed to advancing this promising therapy as quickly as possible to benefit as many patients as possible,' said Mario Rovirosa, Chief Executive Officer of Ferrer.
Fast Track designation is a significant milestone in the drug development process. It is a program that offers the possibility of having more frequent meetings with the FDA to discuss the drug's development, eligibility for Accelerated Approval and Priority Review if relevant criteria are met.
'This designation underscores the importance of expediting the development and review of FNP-223 to address critical unmet needs in patients with this rare and devastating disease,' said Marta Parmar, Ferrer's Chief Quality, Regulatory and Pharmacovigilance Officer.
Progressive supranuclear palsy manifests in patients with symptoms such as difficulty speaking, imbalance, changes in gait, cognitive problems 2-4. PSP has a prevalence of approximately 5 cases per 100,000 people and primarily affects individuals over the age of 60 3. The disease's etiology is believed to be related to the abnormal accumulation of tau proteins in certain areas of the brain, leading to neurodegeneration 3,4. Preclinical models have demonstrated that FNP-223 can prevent the abnormal accumulation of tau proteins in neurons 5. Ferrer now aims to show that this molecule is safe and effective in patients with PSP.
Oscar Pérez, Chief Scientific Officer of Ferrer, also expressed his enthusiasm: "Receiving Fast Track designation is a significant milestone in our journey to provide a transformative treatment for PSP. We are excited to advance our research and hopefully offer a new therapeutic option earlier for patients living with this challenging condition."
About FNP-223
FNP-223 is a new orally administered chemical compound that functions as a reversible and substrate-competitive inhibitor of the O-GlcNAcase (OGA) enzyme 5. Mechanistically, FNP-223 binds to the active site of OGA enzyme. As a result, the inhibitor prevents the substrate from accessing the catalytic pocket, thereby impeding the removal of O-GlcNAc modifications from natural client proteins such as the tau protein. Inhibiting O-GlcNAcase is expected to cause a rapid increase of O-GlcNAcylated (glycosylated) tau proteins, ultimately leading to a reduction in abnormal aggregated tau as neurofibrillary tangles (NFT) over a certain period 5.
Bibliography:
1. ClinicalTrials.gov A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 (Oral Formulation) to Slow the Disease Progression of Progressive Supranuclear Palsy (PSP) (PROSPER). ClinicalTrials.gov [Internet]. Available from: https://www.clinicaltrials.gov/study/NCT06355531.
2. Coughlin DG, Litvan I. Progressive supranuclear palsy: Advances in diagnosis and management. Parkinsonism Relat Disord. 2020 Apr;73:105-116. doi: 10.1016/j.parkreldis.2020.04.014. Epub 2020 May 25.
3. Agarwal S, Gilbert R. Progressive Supranuclear Palsy. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526098/.
4. Rowe JB, Holland N, Rittman T. Progressive supranuclear palsy: diagnosis and management. Pract Neurol. 2021;21(5):376-383. doi: 10.1136/practneurol-2020-002794.
5. Permanne B, Sand A, Ousson S, Nény M, Hantson J, Schubert R, et al. D. O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies. ACS Chem Neurosci. 2022 Apr 20;13(8):1296-1314. doi: 10.1021/acschemneuro.2c00057.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
32 minutes ago
Kraft Heinz pulling certain artificial dyes from its US products in 2027
Kraft Heinz will be pulling certain artificial dyes from its U.S. products starting in 2027 and will no longer roll out new products with the dyes. The move comes nearly two months after U.S. health officials said that they would urge foodmakers to phase out petroleum-based artificial colors in the nation's food supply. Kraft Heinz said Tuesday that almost 90% of its U.S. products already don't contain food, drug & cosmetic colors, but that the products that do still use the dyes will have them removed by the end of 2027. FD&C colors are synthetic additives that are approved by the U.S. Food and Drug Administration for use in food, drugs and cosmetics. The company said that it will instead use natural colors for the products. 'The vast majority of our products use natural or no colors, and we've been on a journey to reduce our use of FD&C colors across the remainder of our portfolio," Pedro Navio, North America President at Kraft Heinz, said in a statement. Kraft Heinz stripped artificial colors, flavors and preservatives from its macaroni and cheese in 2016 and said it has never used artificial dyes in its ketchup. The company plans to work with licensees of its brands to encourage them to remove the dyes. In April Food and Drug Administration Commissioner Marty Makary said at a news conference that the agency would take steps to eliminate the synthetic dyes by the end of 2026, largely by relying on voluntary efforts from the food industry. Health advocates have long called for the removal of artificial dyes from foods, citing mixed studies indicating they can cause neurobehavioral problems, including hyperactivity and attention issues, in some children. The FDA has maintained that the approved dyes are safe and that 'the totality of scientific evidence shows that most children have no adverse effects when consuming foods containing color additives.' The FDA currently allows 36 food color additives, including eight synthetic dyes. In January, the agency announced that the dye known as Red 3 — used in candies, cakes and some medications — would be banned in food by 2027 because it caused cancer in laboratory rats. Artificial dyes are used widely in U.S. foods. In Canada and in Europe — where synthetic colors are required to carry warning labels — manufacturers mostly use natural substitutes. Several states, including California and West Virginia, have passed laws restricting the use of artificial colors in foods. Many U.S. food companies are already reformulating their foods, according to Sensient Colors, one of the world's largest producers of food dyes and flavorings. In place of synthetic dyes, foodmakers can use natural hues made from beets, algae and crushed insects and pigments from purple sweet potatoes, radishes and red cabbage.
Boston Globe
35 minutes ago
- Boston Globe
Kraft Heinz pulling certain artificial dyes from its US products in 2027
The company said that it will instead use natural colors for the products. 'The vast majority of our products use natural or no colors, and we've been on a journey to reduce our use of FD&C colors across the remainder of our portfolio,' Pedro Navio, North America President at Kraft Heinz, said in a statement. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up Kraft Heinz stripped artificial colors, flavors and preservatives from its macaroni and cheese in 2016 and said it has never used artificial dyes in its ketchup. Advertisement The company plans to work with licensees of its brands to encourage them to remove the dyes. In April Food and Drug Administration Commissioner Marty Makary said at a news conference that the agency would take steps to eliminate the synthetic dyes by the end of 2026, largely by relying on voluntary efforts from the food industry. Health advocates have long called for the removal of artificial dyes from foods, citing mixed studies indicating they can cause neurobehavioral problems, including hyperactivity and attention issues, in some children. The FDA has maintained that the approved dyes are safe and that 'the totality of scientific evidence shows that most children have no adverse effects when consuming foods containing color additives.' Advertisement The FDA currently allows 36 food color additives, including eight synthetic dyes. In January, the agency announced that the dye known as Red 3 — used in candies, cakes and some medications — would be banned in food by 2027 because it caused cancer in laboratory rats. Artificial dyes are used widely in U.S. foods. In Canada and in Europe — where synthetic colors are required to carry warning labels — manufacturers mostly use natural substitutes. Several states, including California and West Virginia, have passed laws restricting the use of artificial colors in foods. Many U.S. food companies are already reformulating their foods, according to Sensient Colors, one of the world's largest producers of food dyes and flavorings. In place of synthetic dyes, foodmakers can use natural hues made from beets, algae and crushed insects and pigments from purple sweet potatoes, radishes and red cabbage.
Business Wire
36 minutes ago
- Business Wire
The HRT Club and Posterity Health Join Forces to Advance Inclusive Hormonal Healthcare
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- The HRT Club, a leading pioneer of direct-to-consumer hormone replacement therapies, today announced a strategic partnership with Posterity Health, the leader in expert-led, comprehensive men's health. Together, the two companies are creating a more robust and inclusive approach to hormonal health, providing streamlined access to expert care for individuals and couples alike. The collaboration offers members of The HRT Club a direct pathway to male hormone evaluation and treatment through Posterity Health's best-in-class male management platform that provides both telehealth and in-person care. Share 'Hormonal health is important to all of us,' said Lauren Darisse, Esq., COO & general counsel of The HRT Club. 'This partnership is the beginning of something truly remarkable. We are totally rewriting the rules of hormonal healthcare and making it accessible to everyone — no gatekeeping, just a system made for our members, by our members.' The collaboration offers members of The HRT Club a direct pathway to male hormone evaluation and treatment through Posterity Health's best-in-class male management platform that provides both telehealth and in-person care. Posterity Health patients benefit from access to The HRT Club's affordable, member-driven model for FDA-approved hormone therapies, all without the need for insurance or pharmacy benefit managers. 'Too often, men are placed on hormone therapy without ever speaking to a men's health expert. At Posterity Health, we offer more than a prescription — we provide a trusted partner who understands the full picture, uncovers underlying health issues and creates a personalized care plan to help every man feel his best,' said Barrett Cowan, MD, co-founder and chief medical officer of Posterity Health. 'By partnering with The HRT Club, we're giving individuals and couples a more complete, connected and affordable path to care.' By integrating Posterity Health's male care with HRT Club's existing female hormone care, the partnership fills a long-standing gap in the market: providing coordinated, proactive solutions for couples navigating fertility and midlife health. Many female members of The HRT Club have referred male partners and friends in search of similar support. This partnership is a direct response to their needs and the growing need for expert male care and men's health support. By offering services that speak to the full spectrum of hormonal health, this partnership expands service offerings, increases member lifetime value and reinforces The HRT Club's position as a trusted, community-driven care model. About The HRT Club The HRT Club is on a mission to make hormonal treatments accessible to everyone. Since its launch in April 2024, The HRT Club has quickly become the leading doctor-recommended platform for hormone replacement therapy (HRT). With a network of over 1,400 prescribers and strategic partnerships across the healthcare industry, we are transforming how people access and afford hormonal treatments. Our members enjoy savings of up to 90% on their HRT prescriptions, ensuring that life-changing care is within reach for all who need it. For more information, visit Posterity Health is the leader in expert-led, comprehensive men's health. We provide innovative solutions to optimize hormone levels, address fertility challenges, provide vasectomies and vasectomy reversals and manage long-term health risks, combining cutting-edge technology with expert clinical care. Through our telehealth services, at-home diagnostics and in-person care, Posterity Health is the trusted partner for men at every stage. For more information, visit
